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Introduction
Human papillomavirus (HPV) is one of the most im-
portant carcinogens in humans, classified in Group 1, 
carcinogenic to humans, of the International Agency for 
Research on Cancer (IARC).
The introduction of two prophylactic vaccines that 
can prevent HPV infections and the development of 
precancerous lesions and invasive cancers have opened 
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Abstract
Human papillomavirus (HPV) is one of the most important carcinogens in humans. Vaccines against HPV 
are now considered the first anti-cancer vaccinations. Since 2007, in many developed countries, there have 
been recommendations present for preventive vaccines against HPV. At present, the degree of implementation 
of these recommendations depends on a number of country-specific factors such as the health care system 
organization or the ways of funding. HPV vaccines are primarily to prevent the development of cervical cancer 
and other genital cancers. Therefore, only their long-term effectiveness can be measured, when a correspond-
ingly large cohort of vaccinated teenagers reaches the age of the greatest incidence of these cancers. However, 
great care should be taken in assessing the results of vaccinations due to the possibility of misinterpretation 
and possible erroneous data.
Undoubtedly, teenagers are the target population of HPV vaccines. However, vaccinating young sexually 
active women is also justified from an individual point of view. A 9-valent vaccine has been registered in the 
USA and in Europe – including Poland – as one of the three preventive vaccines. It is recommended to vaccinate 
women between 13 and 26 and men between 13 and 21, previously unvaccinated. It is also recommended to 
vaccinate men aged 26 years or less who have sexual relations with other men and people with reduced im-
munity, including HIV-positive people who have not been vaccinated previously. 
Key words: HPV, human papillomavirus, HPV vaccine.
new perspectives in vaccinology. Vaccines against 
HPV are now considered the first anti-cancer vaccines 
(though, in fact, the first vaccines of this profile are vac-
cines against hepatitis B).
Due to the inability to measure the direct effect of 
anti-cancer vaccines for ethical reasons and time con-
straints of clinical observations, it was assumed that the 
end-point protection surrogate will be preventing cervical 
intraepithelial neoplasia grade 2/3 (CIN2+). The clinical 
tests of both (2-valent and 4-valent) vaccines assumed 
the prevention of CIN2 + [2, 3] as the primary end-point.
Since 2007, in many developed countries, there have 
been recommendations for preventive vaccinations 
against HPV. At present, the degree of implementation 
of these recommendations depends on a  number of 
country-specific factors, such as the health care system 
organization or the ways of funding.
Tab. I. The proven role of HPV infection in malignant neoplasms 
among women [1]
All cancers in women (in developing countries) 16%
All cancers in women 10%
All cancers 5%
Original paper
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Effectiveness of vaccinations against HPV
Human papillomavirus vaccines are primarily to pre-
vent the development of cervical cancer and other gen-
ital cancers. Therefore, only their long-term effective-
ness can be measured when a  correspondingly large 
cohort of vaccinated teenagers reaches the age of the 
greatest incidence of these cancers.
Due to the fact that the transition of chronic HPV 
infections to precancerous lesions (CIN1-3) and to can-
cer lesions is well known, many models were designed 
for the influence of HPV vaccination programs on the 
incidence of diseases. This made it possible to predict 
both clinical and economic effects of vaccinations, prior 
to the availability of both vaccines on the market.
All of these models assumed, however, that universal 
vaccinations of girls combined with cytological screen-
ings significantly affect the incidence of cervical cancer 
and will be favorable from an economic point of view [4]. 
Constantly, new publications are being developed on the 
impact of HPV vaccination strategies on the incidence of 
cervical cancer, which examine new target groups, includ-
ing young boys. Another important element triggered by 
the past experience of anti-HPV vaccination is the alter-
native vaccination schedules reduced to two doses [5].
The result of the observations conducted is the 
knowledge on the impact of HPV vaccination on con-
ditions with shorter natural history than in the case of 
cervical cancer, in particular, the comparison between 
vaccinated and unvaccinated patients with regard to 
the presence of chronic HPV infections, genital warts 
(the 4-valent vaccine) and precancerous lesions (CIN2+). 
However, great care should be taken in assessing 
the results of vaccinations due to the possibility of mis-
interpretation and possible erroneous data. Monitoring 
the prevalence of HPV infections requires answering 
the question of collecting material, detecting and genotyp-
ing HPV from a variety of infected body sites and consid-
ering different screening strategies at the age of starting 
screening, screening interval and the diagnostic tool (HPV 
test). All of these elements can significantly affect the 
percentage of detectable HPV infections and dependent 
lesions [6]. Despite these reservations, however, more and 
more data from many countries provide evidence of the 
effectiveness of prophylactic vaccinations against HPV. 
Undoubtedly, Australia is a country in which a vac-
cination program was introduced in the most compre-
hensive manner and where a high percentage of vac-
cinated young women was achieved in a  short time. 
The proportion of those vaccinated with three doses is 
there, 30% and 70%, respectively, for women in the age 
range of 20-26 and 12-13. In contrast, vaccination with 
at least one dose of the vaccine in the cohorts of wom-
en is at the level of 52% and 83% [7]. 
A  comparative study of the incidence of HPV in 
the cytosmears of Australian women prior to the in-
troduction of vaccination (2005-2007), and after the 
introduction of vaccination (2010-2011) showed that 
the prevalence of HPV vaccine types (6, 11, 16, 18) was 
significantly lower in the vaccinated cohort (6.7% vs. 
28.7%, p < 0.001). A lower prevalence of HPV infection 
was also recorded in both the vaccinated and unvac-
cinated female population, as compared to the pop-
ulation prior to the introduction of vaccination (5.0% 
[OR: 0.11, CI: 0.006-0.21] and 15.8% [OR: 0.42, CI: 0.19-
0.93], respectively) [8].
The impact of vaccination on the incidence of geni-
tal warts is also obvious. In the Australian study evalu-
ating trends in the occurrence of genital warts in 2004-
2011, involving more than 85 000 participants, a huge 
decrease was observed in the proportion of women un-
der 21 and at the age of 21 to 30 who were diagnosed 
with genital warts, from 11.5% in 2007 to 0.85% in 
2011, respectively (a decrease by 92.6%, p < 0.001) and 
11.3% in 2007 to 3.1% in 2011 (a decrease by 72.6%, 
p < 0.001). There was however no decrease recorded in 
the incidence of genital warts in women over 30 years 
of age. An indirect effect of the immunization of young 
women population was their reduced incidence of gen-
ital warts, 81.8% and 51.1%, respectively, in the popu-
lation of young heterosexual men (under 21 and at the 
age of 21-30). There was no decrease in the incidence 
of genital warts in men over 30 [9]. 
A third Australian study by Brotherton et al. showed 
a decrease in high-grade epithelial lesions in the cervix 
(CIN2 + and AIS – adenocarcinoma in situ) among vacci-
nated women below 18 covered by the vaccination pro-
gram, as compared with the period before the introduc-
tion of population-based vaccination (2003-2007) to 
the period of 2007-2009 (post-vaccination). There has 
been a 50% decrease in the incidence of CIN2+ and AIS 
(p = 0.003) from 0.85% in 2006 to 0.22% in 2009 [10]. 
Evidence of the protective effect of vaccination 
against HPV also comes from the Nordic countries. 
A study carried out in Denmark demonstrated that while 
the incidence of genital warts was 2% in the period be-
fore immunization, the condition was absent after the 
introduction of vaccination in the population (population 
coverage was 85%) of females aged 16-17. There was no 
indirect effect of the vaccination of girls on the incidence 
of genital warts in young men [11]. 
In all of the Nordic countries, a long-term follow-up 
program was introduced for women covered by the pro-
gram of preventive vaccination against HPV. Because all 
of the women in the placebo group in the Future II study 
were vaccinated after 60 months for ethical reasons, 
it is not currently possible to determine the effects 
of vaccination [12]. It should be noted, however, that 
within 8 years of the observation there was no case of 
CIN2+ associated with HPV 16/18 in women from the 
group vaccinated according to the protocol of vaccina-
tion [13]. 
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In the USA, the degree of vaccinating girls aged 
(13-17) remains low (32% in 2010). Nevertheless, data 
from the National Health and Nutrition Examinations 
Surveys clearly show (56%) a  decrease in HPV infec-
tions with compact types in the case of vaccinated girls 
aged 14-19 years, comparing the periods 2003-2006 to 
2007-2010). The efficacy of vaccination (assuming at 
least one dose) was rated at 82% [14]. 
Studies of the vaccine against HPV have shown 
varying degrees of cross-immunity against the types of 
the virus not present in the vaccines. Such an unexpect-
ed mechanism was observed, e.g. in the PATRICIA study 
(Papilloma Trial Against Cancer in Young Adults) eval-
uating the efficacy of a bivalent vaccine. The efficacy 
of the vaccine was demonstrated with respect to the 
types of HPV that cause the formation of genital warts. 
The effectiveness of the 6-month vaccine was 34.5% 
against HPV 6/11, 34.9% against HPV 6 and 49.5% 
against HPV 74 (all statistically significant). Unfortu-
nately, in the long-term perspective, it was observed 
that the cross-immunity begins to fade with time, and 
after a period of 6.4 years and 8 years, there was no 
statistical significance [15]. In the UK, the vaccination 
program consisted of girls aged 12 (reaching 80% cov-
erage of the population and an additional 40% in the 
revaccination program to 18 years old). Reducing the 
incidence of genital warts was 11% to 16% in women 
aged 18 and 15. 
Human papillomavirus is associated with a  risk of 
not only lesions in the genital area, but also a significant 
proportion of cancers of the head and neck. The Cen-
tre for Disease Control and Prevention (CDC) envisages 
a significant effect of prophylactic vaccination on the re-
duction of morbidity and mortality from cancers of the 
head and neck [16]. 
It should be remembered that in a small percentage 
of the cases of cancer of the vulva, vagina, anus, and 
especially penis, DNA HPV 6 is recorded, from the low-
risk group [17].
Observational studies are also ongoing with respect 
to the possibility of replacing the niche left by the HPV 
types included in the vaccine by other HPV types. Howev-
er, due to the characteristics of HPV (among other things, 
the possibility and incidence of multiple infections), it is 
now unlikely that such a phenomenon occurred. 
The possibility of reducing the doses of the vaccine 
entails several advantages. First of all, it enables an in-
crease in the population covered by the vaccination and 
results in its cost reduction, which can be used, e.g. to 
extend the cohorts undergoing immunization.
Two studies of the effectiveness of the two-dose im-
munization schedule (Romanowski et al. 2011 – I/II phase 
study (HPV048) and Puthanakit et al. 2013 – III study 
phase (HPV-070) demonstrated clinical efficacy [18, 19]. 
With regard to the conditions associated with HPV 16 
and 18, the two-dose immunization vaccination schedule 
for girls aged 9-14 was not immunologically less effective 
than the three-dose schedule in the population of girls 
aged 15-25 [20]. The immune response 48 months after 
vaccination with two doses was still at a high level [21]. 
The European Medicine Agency (EMA) approved, in 2013, 
the two-dose bivalent vaccination of girls aged 9-14. 
For the 4-valent vaccine, there were no ad hoc stud-
ies planned to assess the change of the vaccination 
schedule of young girls. Nevertheless, in some coun-
tries, independently, studies were conducted on the 
off-label use of the vaccine in the two-dose schedule. 
The study conducted in Canada on a population of 830 
girls stratified according to their age showed no inferi-
ority of the two-dose schedule over the three-dose one 
[22]. In 2014, the EMA issued a positive opinion on the 
possibility of adapting the 4-valent vaccine to the two-
dose schedule (M0,6) in girls aged 9-13. 
In June 2015, the first reports were published on the 
effectiveness of preventive vaccination with the one-dose 
schedule, particularly in developing countries [23]. So far, 
45 countries in the world (mainly developed) have intro-
duced a population prophylactic vaccination program. 
Despite the efficacy and safety profile of prophy-
lactic vaccines against HPV, the social acceptance of 
vaccination and the percentage of vaccinated popula-
tions remain far from optimal. According to data from 
the European Centre for Disease Prevention and Con-
trol of Diseases (ECDC), there are several reasons for 
such a state of affairs. The most important ones seem 
to be: low knowledge of HPV vaccines and prophylactic 
vaccines, high cost of vaccination, low expected effi-
ciency of vaccines, and alleged and actual side effects 
of vaccines. An important barrier is the fear of parents 
whether vaccinations increase the promiscuity and 
risky sexual behaviors of their children. From this point 
of view, the paper by Bednarczyk et al. is important; it 
did not show an increased percentage of sexual activi-
ty in girls immunized at the age of 11-12, observed for 
three years [24]. 
Undoubtedly, teenagers are the target population of 
HPV vaccines. However, vaccinating young, sexually ac-
tive women is also justified from an individual point of 
view [25]. First of all, the risk of infections with all four 
HPV types present in the vaccines is negligible (< 1%), 
secondly, the vaccines are effective against the HPV 
types with which the woman was not infected at the 
time of immunization and, finally, there is evidence that 
vaccines provide protection against the HPV types that 
were cured (seropositive but DNA-negative). All sexually 
active women are constantly exposed to HPV infections. 
As far as vaccinating men is concerned, it was shown 
that prophylactic vaccinations against HPV are highly 
(90%) effective in the prevention of condyloma acumi-
nata [26]. Efficacy against anal intraepithelial neoplasia 
is estimated to be 92% and, therefore, the vaccine would 
be the most effective in homosexual men [27]. 
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Organizational experience with respect 
to anti-HPV vaccinations
The guidelines for the use of vaccines developed by 
the European Centers for Disease Prevention (ECDC) 
include detailed information on the legitimacy of their 
use, efficiency, safety, and the suggested target group. 
They also recommended monitoring vaccination pro-
grams, which have been implemented in some coun-
tries. Previous studies on HPV vaccination programs in 
Europe helped to create a map of areas covered by the 
vaccination programs and their structure. The VENICE 
study showed large differences between the programs 
and focused on the decision-making processes for the 
implementation of the programs. Studies conducted 
in Central and Eastern Europe also provided informa-
tion on the programs there, the incidence of HPV and 
the distribution of different types of the virus, which 
is a  preliminary requirement to assess the impact of 
vaccinations. The studies provided detailed informa-
tion on how the programs developed, how they were 
implemented, and they emphasize the role of knowing 
the structure of infections in a given country prior to 
starting the program. 
Vaccination programs against HPV require financial 
and personal involvement. To achieve the expected re-
sults, there is a  need for continued monitoring, eval-
uation and optimization of the activities conducted. 
Combining medical records enables continuous surveil-
lance of the key data collected during screening, the 
incidence of cancer registers and the records of immu-
nization: immunization coverage, the rate of unfinished 
vaccination cycles, the incidence of CIN, cancer, genital 
warts and HPV infections, as well as side effects of vac-
cines. Such connection of databases, however, requires 
a  substantial contribution to the assessment of indi-
vidual epidemiological phenomena and the structure 
of the overall protection of personal data. Furthermore, 
registers should be interconnected at the level of in-
dividual records, which would enable demonstrating 
direct relationships of a particular case in individual da-
tabases. As the participants of the first study conduct-
ed get older, it will be possible to assess the long-term 
impact of vaccinations.
Prospects for HPV vaccination
The nine-valent vaccine was registered by the FDA 
on December 10, 2014 for use in women of 9 to 26 and 
men from 9 to 15 [28]. 
The Advisory Committee on Immunization Practic-
es (ACIP), in February 2015, recommended the use of 
the 9-valent vaccine as one of three possible vaccines 
against HPV. Recommendations for vaccinations against 
HPV indicate the population of 11- or 12-year-olds. ACIP 
recommends vaccinations of women between 13 and 
26 and men between 13 and 21, previously unvaccinat-
ed. It is also recommended to vaccinate men aged 26 
or less who have sexual relations with other men and 
people with reduced immunity, including HIV-positive 
people who have not been vaccinated previously. 
The 9-valent vaccine, just as the 4-valent one, con-
tains a VLP (a virus-like antigen) for HPV 6, 11, 16, 18. 
Additionally, it contains a  VLP for HPV 31, 33, 45, 52 
and 58 [29]. 
In 2013-2015, an ACIP working group analyzed the 
clinical efficacy, immunogenicity and safety of the 9-va-
lent vaccine. The recommendations were considered as 
category A [30].
Efficacy, safety and immunogenicity  
of the 9-valent vaccine
The III phase of the study compared the efficacy 
of the 4- and 9-valent vaccines in 14 thousand wom-
en aged 16-26. The efficacy of the 9-valent vaccine in 
preventing CIN2+, VIN 2 and 3, VAIN 2 and 3 caused by 
HPV 31, 33, 45, 52 and 59 was 96.7% (women vaccinated 
with three doses within a year, seronegative prior to the 
first dose, still seronegative one month after the third 
dose) [29, 31]. Efficacy against CIN2+, HPV 31, 33, 45, 52 
and 58 was 96.3% and 96% for a persistent infection in 
a six-month observation period [31]. Most infections in 
both treatment groups were caused by HPV 6, 11, 16, 18. 
The immunogenicity of the 9-valent vaccine, compara-
ble to the 4-valent vaccine, was used to demonstrate 
the efficacy of the vaccine in preventing HPV 6, 11, 16, 
18. The geometric mean titers of antibodies one month 
after the third dose were satisfactory for HPV 6, 11, 16, 
18, 2 in the group vaccinated with the 9-valent vaccine – 
seroconversion rate of 99% was found for all 9 subtypes 
of HPV. 
The 9-valent vaccine immunogenicity assessment 
was made in 2.4 thousand women and men from 9 to 
15 and 400 women aged 16-26. The seroconversion 
rate of 99% was found for all 9 types of HPV, but the 
mean titers of antibodies were significantly higher in 
younger women.
 A study comparing the immunogenicity of the 4-va-
lent and the 9-valent vaccines in 600 women aged 9 to 
15 showed the seroconversion rate for HPV 6, 11, 16, 
18 of 100% in both groups, and mean titers of antibod-
ies in the 9-valent group did not differ from those found 
in the 4-valent group. 
Another study examined the immunogenicity of the 
9-valent vaccine in men from 16 to 26 years of age, as 
compared with women in the same age range. The sero-
conversion rate of over 99% was found in both groups 
for all 9 types, the mean titers of antibodies were com-
parable [32].
Research on the 9-valent vaccine immunogenicity was 
assessed in a simultaneous combination with other vac-
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cines: the 4-valent conjugate vaccine against the menin-
gitis (Menactra) and vaccines against tetanus, diphtheria 
and pertussis (Adacel). All groups reported titers of anti-
bodies comparable to the mean. The safety of 9-valent 
vaccines was assessed in 4 studies under the auspices 
of the FDA [32]. The vaccine was well tolerated, and most 
of the side effects were associated with pain on injection, 
pruritus and rash. The severity of these ailments was mild 
or moderate. The safety profile was similar for the 4- and 
9-valent vaccines.
Contraindications and precautions
Human papillomavirus vaccines are contraindicated 
in patients with previously demonstrated hypersensi-
tivity to vaccine components. The 4- and 9-valent vac-
cines are contraindicated in patients who are allergic 
to yeast. The 2-valent vaccine should not be used in 
people who are allergic to latex. 
The vaccine is not recommended in pregnant wom-
en [33]. In women vaccinated with the starting dose, 
who subsequently became pregnant, subsequent doses 
should be postponed until the end of pregnancy. Preg-
nancy tests do not need to be performed in women prior 
to vaccination. If the vaccination took place during preg-
nancy, there is no need for intervention. New guidelines 
have been established for the 9-valent vaccine in preg-
nancy [29]. Registrations for pregnant women regard-
ing the 4- and 2-valent vaccines were closed after the 
intervention of the FDA [33, 34]. Exposure to vaccination 
during pregnancy should be reported. Screening for cer-
vical cancer is recommended for women over 21 and 
continued to the age of 65 for all vaccinated and unvac-
cinated women [35].
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